欢迎光临吉康旅！
For with non- cell lung with EGFR , EGFR are the -line , and they are to in of -free , rate, and side . Next, let's take a look at the role of EGFR - . ( ), name , is a , anti- by the EGFR .
At , has been for in many the , and its drug more than ten ago. In fact, the of was not . the FDA its in 2003 as a -line drug for in the , ISEL that did not an in rate into a for the , at the time, Erlo was for the same on in , led to the FDA the in June 2005.
不过，阿斯利康并没有放弃，将吉非替尼的市场重新定位到亚洲国家，并进行了实验研究。试验结果表明，吉非替尼不劣于多西他赛，可作为二线治疗。试验进一步验证了吉非替尼在亚洲、从不吸烟和腺癌人群中的 PFS 更长。基于这两项研究，吉非替尼在欧洲上市。随后，基于IFUM试验，吉非替尼重返美国市场。
免责声明： 本站关于疾病和药品的介绍仅供参考，实际治疗和用药方案请咨询专业医生和药师。
微信扫码◀
免费咨询电话
疾病药品类目导航
资讯中心